![](/img/cover-not-exists.png)
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
Mead, G. M., Barrans, S. L., Qian, W., Walewski, J., Radford, J. A., Wolf, M., Clawson, S. M., Stenning, S. P., Yule, C. L., Jack, A. S.Volume:
112
Language:
english
Journal:
Blood
DOI:
10.1182/blood-2008-03-145128
Date:
September, 2008
File:
PDF, 1.07 MB
english, 2008